Related Experiment Video
Updated: May 6, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Advances in the study and treatment of genetic cardiomyopathies
Victoria N Parikh1, Sharlene M Day2, Neal K Lakdawala3
1Stanford Center for Inherited Cardiovascular Disease, Stanford School of Medicine, Stanford, CA, USA.
Insights
Cardiomyopathies, heart muscle disorders, are classified into hypertrophic (HCM), dilated (DCM), and arrhythmogenic (ACM) types. Genetic insights are driving precision diagnosis, management, and novel therapies, including gene treatments, for these conditions.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Cardiomyopathies are primary heart muscle diseases with distinct phenotypes.
- Key types include hypertrophic (HCM), dilated (DCM), and arrhythmogenic (ACM) cardiomyopathies.
- These conditions are characterized by specific morphological and functional abnormalities.
Purpose of the Study:
- To highlight the impact of genetic discoveries on understanding cardiomyopathies.
- To discuss the development of precision diagnostics and mechanistically based treatments.
- To explore emergent gene therapies for cardiomyopathy.
Main Methods:
- Review of genetic discoveries in cardiomyopathy.
- Analysis of new therapeutic strategies.
- Integration of molecular insights with clinical features.
Main Results:
- Genetic research is improving diagnostic precision.
- Mechanistically informed therapies are being developed.
- Gene therapies show promise for restoring cardiac function.
Conclusions:
- Genetic discoveries are revolutionizing cardiomyopathy care.
- New treatments offer hope for improved patient outcomes.
- This marks a new era in cardiac biology and patient management.
Abstract:
Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and arrhythmogenic cardiomyopathy (ACM), with right, left, or biventricular involvement and arrhythmias out of proportion to systolic dysfunction. Genetic discoveries of the molecular basis of disease are paving the way for greater precision in diagnosis and management and revealing mechanisms that account for distinguishing clinical features. This deeper understanding has propelled the development of new treatments for cardiomyopathies: disease-specific, mechanistically based medicines that counteract pathophysiology, and emergent gene therapies that aim to intercept disease progression and restore cardiac physiology. Together, these discoveries have advanced fundamental insights into cardiac biology and herald a new era for patients with cardiomyopathy.
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

